FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM
The U.S. Food and Drug Administration (FDA) has granted…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Ready-to-use bortezomib formula Boruzu OK’d for multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved…
Blood Cancer Awareness Month is an opportunity to #kNOwMyeloma
Supporters are gearing up to learn, educate, and fundraise…
FDA declines linvoseltamab decision for RRMM due to facility issue
The U.S. Food and Drug Administration (FDA) has rejected…
Phase 3 trial of CAR T-cell therapy anito-cel for RRMM opens
Kite Pharma has initiated iMMagine-3, a global Phase…
First-line induction therapy with Sarclisa delays myeloma progression
Adding Sarclisa (isatuximab) to standard induction therapy for…
